Э Г Гемджян
National Medical Research Center for Hematology · 190 works · 365 citations · h-index 9
Top works
- Clinical and morphological features of different types of Castleman’s disease
- Safe and effective treatment of follicular lymphoma in patients with HCV ‐infection
- CHEMOTHERAPY ACCORDING TO THE R-mNHL-BFM-90 PROTOCOL IN COMBINATION WITH LENALIDOMIDE AS THE FIRST LINE THERAPY IN PATIENTS WITH MUM1-POSITIVE DIFFUSIVE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA GRADE 3B
- Hemostatic Disorders and Thrombotic Events in Multiple Myeloma Patients during Peripheral Blood Stem Cell Mobilization
- ESICM LIVES 2016: part two
- [Allogenic bone marrow transplantation in chronic myeloid leukemias].
- The Results of the Russian Clinical Trial of Mesenchymal Stromal Cells (MSCs) in Severe Neutropenic Patients (pts) with Septic Shock (SS) (RUMCESS trial)
- Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues
- Therapy for Burkitt’s lymphoma according to the BL-M-04 protocol: 12-year experience
- Epidemiology of uveal melanomas in Moscow
- Efficacy of Maintenance Therapy Following Auto-HSCT Depending on MRD Status in Patients with Multiple Myeloma
- Perianal infection in patients with hemoblastosis: Risk factors and possibilities of prevention
- Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications
- [Thrombocytopenia and postoperative analgesia].
- Molecular analysis of immunoglobulin genes in the tumor B cells in splenic marginal zone lymphoma
- ADAPTATION AND VALIDATION OF THE STRONGKIDS NUTRITIONAL RISK SCREENING TOOL FOR THE RUSSIAN LANGUAGE SPEAKING AUDIENCE
- MICROSURGICAL DISCECTOMY IN THE LIMBAR SPINE: EFFICIENCY, PAIN SYNDROME AND OBESITY
- Follicular lymphoma: first - line selection criteria of treatment
- PERIANAL INFECTIOUS COMPLICATIONS IN PATIENTS WITH GRANULOCYTOPENIA AND HAEMATOLOGICAL MALIGNANCIES
- Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma